Role of p53 family members p73 and p63 in human hematological malignancies

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2116-2129

  Alexandrova, Evguenia M ^a   Moll, Ute M ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

leukemia; lymphoma; methylation; myeloma; p63; p73

Indexed keywords

CYCLIN DEPENDENT KINASE; DAUNORUBICIN; ISOPROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR RUNX1; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLELE; ANTINEOPLASTIC ACTIVITY; BLOOD CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM; CHRONIC MYELOID LEUKEMIA; DNA METHYLATION; EXON; GENE DELETION; GENE MUTATION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGOMERIZATION; ORGANOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL; UPREGULATION;

ANIMALS; DNA METHYLATION; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA; LYMPHOMA; MEMBRANE PROTEINS; MICE; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84867188869     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.684348     Document Type: Review

References (123)

1. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012 Jan 24. [Epub ahead of print]
2. Cheung KJ, Horsman DE, Gascoyne RD. The signif cance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009;146:257-269.
3. Donehower LA, Harvey M, Slagle BL, et al. Mice def cient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
4. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
5. Talos F, Moll UM. Role of the p53 family in stabilizing the genome and preventing polyploidization. Adv Exp Med Biol 2010;676:73-91.
6. Moll UM, Wolf S, Speidel D, et al. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005;17:631-636. (Pubitemid 41540413)
7. R u f ni A, Agostini M, Grespi F, et al. p73 in cancer. Genes Cancer 2011;2:491-502.
8. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Difer 2011;18:1487-1499.
9. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004;2:371-386. (Pubitemid 39031071)
10. Stiewe T, Zimmermann S, Frilling A, et al. Transactivation-def cient deltaTA-p73 acts as an oncogene. Cancer Res 2002;62:3598-3602. (Pubitemid 34728831)
11. Talos F, Nemajerova A, Flores ER, et al. p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell 2007;27:647-659. (Pubitemid 47238632)
12. Li C, Feng Y, Coukos G, et al. Therapeutic microRNA strategies in human cancer. AAPS J 2009;11:747-757.
13. Knouf EC, Garg K, Arroyo JD, et al. An integrative genomic approach identif es p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 2012;40:499-510.
14. Agostini M, Tucci P, Killick R, et al. Neuronal dif erentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 2011;108:21093-21098.
15. Antonini D, Russo MT, De Rosa L, et al. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol 2010;130:1249-1257.
16. Rao DS, O'Connell RM, Chaudhuri AA, et al. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010;33:48-59.
17. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. J Am Med Assoc 2011;305:59-67.
18. Su X, Chakravarti D, Cho MS, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467:986-990.
19. Rivetti di Val Cervo P, Lena AM, Nicoloso M, et al. p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci USA 2012; 109:1133-1138.
20. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-11593. (Pubitemid 46094168)
21. Wang W, Zhao LJ, Tan YX, et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012 Mar 13. [Epub ahead of print]
22. Yang C, Cai J, Wang Q, et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012;124:325-334.
23. Huang Y, Chuang A, Hao H, et al. Phospho-Δ Np63α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Difer 2011;18:1220-1230.
24. Huang Y, Guerrero-Preston R, Ratovitski EA. Phospho-Δ Np63 α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle 2012;11:1247-1259.
25. Ory B, Ramsey MR, Wilson C, et al. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 2011;121:809-820.
26. Batliner J, Buehrer E, Fey MF, et al. Inhibition of the miR-143/145 cluster attenuated neutrophil dif erentiation of APL cells. Leuk Res 2012;36:237-240.
27. Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 2010;24:2754-2759.
28. Yang A, Walker N, Bronson R, et al. p73-def cient mice have neurological, pheromonal and inf ammatory defects but lack spontaneous tumours. Nature 2000;404:99-103. (Pubitemid 30143141)
29. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7:363-373. (Pubitemid 40544653)
30. Nemajerova A, Palacios G, Nowak NJ, et al. Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. PLoS One 2009;4:e7784.
31. Griesmann H, Schlereth K, Krause M, et al. p53 and p73 in suppression of Myc-driven lymphomagenesis. Int J Cancer 2009;124:502-506.
32. Nemajerova A, Petrenko O, Tr ü mper L, et al. Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J Clin Invest 2010;120:2070-2080.
33. Tomasini R, Tsuchihara K, Wilhelm M, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008;22:2677-2691.
34. Wilhelm MT, Ruf ni A, Wetzel MK, et al. Isoform-specif c p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2008;24:549-560.
35. Zaika AI, Slade N, Erster SH, et al. DeltaNp73, a dominantnegative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-780.
36. Sahu GR, Das BR. Alteration of p73 in pediatric de novo acute lymphoblastic leukemia. Biochem Biophys Res Commun 2005;327:750-755. (Pubitemid 40092813)
37. Meier M, den Boer ML, Meijerink JP, et al. Dif erential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2006;20:1377-1384. (Pubitemid 44084050)
38. Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5'CpG island methylation. Cancer Res 1999;59:3352-3356. (Pubitemid 29334490)
39. Liu M, Li R, Hayashi Y, et al. Study on abnormal expression of the p73 gene in childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 2002;23:239-242.
40. Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113-1120. (Pubitemid 29361845)
41. Gutierrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia 2003;17:1845-1850. (Pubitemid 37185261)
42. Bueso-Ramos C, Xu Y, McDonnell TJ, et al. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 2005;23:3932-3939. (Pubitemid 46218696)
43. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Lack of CpG island methylator phenotype def nes a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 2005;23:7043-7049.
44. Abd El-Hamid TM, Mossallam GI, Sherisher MA. The clinical implications of methylated p15 and p73 genes in adult acute lymphoblastic leukemia. J Egypt Natl Cancer Inst 2010;22:175-184.
45. Scaruf P, Casciano I, Masiero L, et al. Lack of p73 expression in mature B-ALL and identif cation of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL dif erentiation. Leukemia 2000;14:518-519. (Pubitemid 30142885)
46. Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002;8:2217-2224. (Pubitemid 34753593)
47. Yang H, Kadia T, Xiao L, et al. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 2009;113:1892-1898.
48. Garcia-Manero G, Bueso-Ramos C, Daniel J, et al. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 2002;8:1897-1903. (Pubitemid 34633752)
49. Canalli AA, Yang H, Jeha S, et al. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 2005;29:881-885. (Pubitemid 40840715)
50. Shen L, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identif es a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003;101:4131-4136. (Pubitemid 36857895)
51. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. CpG island methylator phenotype redef nes the prognostic ef ect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006;12:4845-4850. (Pubitemid 44338569)
52. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010-1022.
53. Novak U, Grob TJ, Baskaynak G, et al. Overexpression of the p73 gene is a novel f nding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol 2001;12:981-986. (Pubitemid 32725773)
54. Leupin N, L ü thi A, Novak U, et al. P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004;45:1205-1207. (Pubitemid 38584904)
55. Casabonne D, Reina O, Benavente Y, et al. Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph. Haematologica 2011;96:323-327.
56. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer 2001;85:204-208. (Pubitemid 32695740)
57. Martinez-Delgado B, Melendez B, Cuadros M, et al. Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer 2002;102:15-19.
58. Herranz M, Urioste M, Santos J, et al. Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas. Leukemia 2000;14:1325-1327. (Pubitemid 30445047)
59. Stof el A, Filippa D, Rao PH. The p73 locus is commonly deleted in non-Hodgkin's lymphomas. Leuk Res 2004;28:1341-1345. (Pubitemid 39314414)
60. Cuadros M, Ribas G, Fern á ndez V, et al. Allelic expression and quantitative RT-PCR study of TAp73 and DeltaNp73 in non-Hodgkin's lymphomas. Leuk Res 2006;30:170-177. (Pubitemid 41773337)
61. van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic prof ling of cutaneous T-cell lymphoma:promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005;23:3886-3896. (Pubitemid 46218691)
62. Kaneko Y, Sakurai S, Hironaka M, et al. Distinct methylated prof les in Helicobacter pylori dependent and independent gastric MALT lymphomas. Gut 2003;52:641-646. (Pubitemid 36528863)
63. Kondo T, Oka T, Sato H, et al. Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol 2009;35:547-557.
64. Gonzalez-Gomez P, Bello MJ, Arjona D, et al. CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients. Cancer Genet Cytogenet 2003;142:21-24. (Pubitemid 36349258)
65. Chu LC, Eberhart CG, Grossman SA, et al. Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 2006; 119:2487-2491. (Pubitemid 44546976)
66. Sato H, Oka T, Shinnou Y, et al. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol 2010;176:402-415.
67. Siu LL, Chan JK, Wong K F, et al. Specif c patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved. Am J Pathol 2002;160:59-66. (Pubitemid 34052266)
68. Siu LL, Chan JK, Wong KF, et al. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 2003;122:70-77. (Pubitemid 36819340)
69. Kawamata N, Inagaki N, Mizumura S, et al. Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 2005;74:424-429. (Pubitemid 40545568)
70. Pei JH, Luo SQ, Zhong Y, et al. The association between non-Hodgkin lymphoma and methylation of p73. Tumour Biol 2011; 32:1133-1138.
71. Hummel M, Bentink S, Berger H, et al. A biologic def nition of Burkitt's lymphoma from transcriptional and genomic prof ling. N Engl J Med 2006;354:2419-2430. (Pubitemid 43855045)
72. Stirewalt DL, Clurman B, Appelbaum FR, et al. p73 mutations and expression in adult de novo acute myelogenous leukemia. Leukemia 1999;13:985-990. (Pubitemid 29360914)
73. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004;18:1687-1692. (Pubitemid 39386348)
74. Hess CJ, Errami A, Berkhof J, et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 2008;49:1132-1141. (Pubitemid 351943260)
75. Galm O, Wilop S, L ü ders C, et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 2005;84(Suppl. 1):39-46.
76. Grif ths EA, Gore SD, Hooker CM, et al. Epigenetic dif erences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010;5:590-600.
77. Talos F, Nemajerova A, Flores ER, et al. p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell 2007;27:647-659. (Pubitemid 47238632)
78. Stanganelli C, Arbelbide J, Fantl DB, et al. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined signif cance. Ann Hematol 2010;89:191-199.
79. Peters UR, Tschan MP, Kreuzer KA, et al. Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res 1999; 59:4233-4236. (Pubitemid 29418734)
80. Tschan MP, Grob TJ, Peters UR, et al. Enhanced p73 expression during dif erentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun 2000;277:62-65.
81. Rizzo MG, Giombini E, Diverio D, et al. Analysis of p73 expression pattern in acute myeloid leukemias:lack of deltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 2004;18:1804-1809. (Pubitemid 39530009)
82. Mainardi S, Pelosi A, Palescandolo E, et al. deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid dif erentiation. Cell Death Difer 2007;14:1968-1971. (Pubitemid 350011672)
83. Bisso A, Collavin L, Del Sal G. p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des 2011;17:578-590.
84. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007;26:2220-2225. (Pubitemid 46536648)
85. Bailey SG, Sanchez-Elsner T, Stephanou A, et al. Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 2010;15:541-552.
86. Di Leva G, Briskin D, Croce CM. MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Upsala J Med Sci 2012 Feb 21. [Epub ahead of print]
87. Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res 2010;184:131-157.
88. Litzow MR. Novel therapeutic approaches for acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011;25:1303-1317.
89. Marks PW. Decitabine for acute myeloid leukemia. Expert Rev Anticancer Ter 2012;12:299-305.
90. Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic prof les in models of DLBCL. Blood 2011;118:5506-5516.
91. Alhosin M, Sharif T, Mousli M, et al. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 2011;30:41-50.
92. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713. (Pubitemid 29197649)
93. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718. (Pubitemid 29197650)
94. Keyes WM, Vogel H, Koster MI, et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 2006;103:8435-8440. (Pubitemid 43838473)
95. Guo X, Keyes WM, Papazoglu C, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol2009;11:1451-1457.
96. Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta 2011;1816:57-66.
97. Rinne T, Brunner HG, van Bokhoven H. p63-associated disorders. Cell Cycle 2007;6:262-268.
98. Akahoshi K, Sakazume S, Kosaki K, et al. EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene and B cell lymphoma. Am J Med Genet A 2003;120A:370-373. (Pubitemid 37063772)
99. Cabanillas M, Torrelo A, Monteagudo B, et al. A novel heterozygous point mutation in the p63 gene in a patient with ectodermal dysplasia associated with B-cell leukemia. Pediatr Dermatol 2011; 28:707-710.
100. Balci S, Engiz O, Okten G, et al. A 19-year follow-up of a patient with type 3 ectrodactyly-ectodermal dysplasia-clefting syndrome who developed non-Hodgkin lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e91-e95.
101. Yamaguchi H, Inokuchi K, Sakuma Y, et al. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 2001;15:1729-1734. (Pubitemid 33061840)
102. Pruneri G, Fabris S, Dell'Orto P, et al. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplif cation. J Pathol 2005;206:337-345. (Pubitemid 40903198)
103. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression prof les in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501. (Pubitemid 34193969)
104. Park CK, Oh YH. Expression of p63 in reactive hyperplasias and malignant lymphomas. J Korean Med Sci 2005;20:752-758.
105. Chilosi M, Zam ò A, Brighenti A, et al. Constitutive expression of deltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003;443:175-183. (Pubitemid 37056143)
106. Hedvat C V, Teruya-Feldstein J, Puig P, et al. Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 2005;13:237-242. (Pubitemid 41209016)
107. Fukushima N, Satoh T, Sueoka N, et al. Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci 2006;97:1050-1055. (Pubitemid 44322553)
108. Gualco G, Weiss LM, Bacchi CE. Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. HumPathol 2008;39:1505-1510.
109. Zuo XL, Zhou Y, Zhou X, et al. Expression of survivin and P63 protein in B cell non-Hodgkin's lymphoma and their effects on cell apoptosis and proliferation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007;15:99-102.
110. Hallack Neto AE, Siqueira SA, Dulley FL, et al. p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol 2009;62:77-79.
111. Nylander K, Vojtesek B, Nenutil R, et al. Dif erential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427. (Pubitemid 35446994)
112. Alisi A, Giannini C, Spaziani A, et al. Hepatitis C virus core protein enhances B lymphocyte proliferation. Digest Liver Dis 2007;39 (Suppl. 1):S72-S75. (Pubitemid 47541926)
113. Serber Z, Lai HC, Yang A, et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002;22:8601-8611. (Pubitemid 35397175)
114. Ghioni P, Bolognese F, Duijf PH, et al. Complex transcriptional effects of p63 isoforms: identif cation of novel activation and repression domains. Mol Cell Biol 2002;22:8659-8668. (Pubitemid 35397180)
115. Koster MI, Kim S, Mills AA, et al. p63 is the molecular switch for initiation of an epithelial stratif cation program. Genes Dev 2004;18:126-131. (Pubitemid 38141780)
116. Blandino G, Moll UM. p63 regulation by microRNAs. Cell Cycle 2009;8:1466-1467.
117. Manni I, Artuso S, Careccia S, et al. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 2009;23:3957-3966.
118. Gutiérrez MI, Siraj AK, Ibrahim MM, et al. Childhood and adult ALL: dif erences in epigenetic lesions associated with cell cycle genes. Am J Hematol 2005;80:158-160. (Pubitemid 41434202)
119. Toso A, Aluf P, Capello D, et al. Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands. Head Neck 2009;31:1181-1187.
120. Au WY, Fung A, Ma ES, et al. HLA associations, microsatellite instability and epigenetic changes in thyroid lymphoma in Chinese. Leuk Lymphoma 2007;48:531-534. (Pubitemid 46487761)
121. Ekmekci CG, Gutié rrez MI, Siraj AK, et al. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 2004;77:233-240. (Pubitemid 39430701)
122. Seidl S, Ackermann J, Kaufmann H, et al. DNA-methylation analysis identif es the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004;100:2598-2606. (Pubitemid 38715765)
123. Chim CS, Kwong YL, Fung TK, et al. Methylation prof ling in multiple myeloma. Leuk Res 2004;28:379-385. (Pubitemid 38199946)